Free tool
FAERS Monitor: Xiaflex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125338 or its brand name (Xiaflex, Collagenase Clostridium Histolyticum). Reports on generic versions are filed under their own applications.
Reports
5,433
Serious
1,380
25% of reports
Hospitalization
247
Death reported
61
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,359
- contusion671
- swelling576
- pain506
- penile swelling479
- fracture of penis465
- penile contusion449
- injection site pain322
- penile pain311
- inappropriate schedule of product administration214
- injection site swelling213
- condition aggravated208
- penile haematoma204
- peyronie^s disease204
- corpora cavernosa surgery197
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 33 |
| 2011 | 153 |
| 2012 | 51 |
| 2013 | 20 |
| 2014 | 43 |
| 2015 | 361 |
| 2016 | 422 |
| 2017 | 332 |
| 2018 | 418 |
| 2019 | 656 |
| 2020 | 742 |
| 2021 | 589 |
| 2022 | 530 |
| 2023 | 303 |
| 2024 | 324 |
| 2025 | 304 |
| 2026 | 152 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,726 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| corpora cavernosa surgerySignal | 197 | 152644.9 | 62860.6 | 740,556 |
| penile contusionSignal | 449 | 57984.4 | 40106.0 | 1,626,935 |
| fracture of penisSignal | 465 | 29056.8 | 22322.5 | 1,586,089 |
| penile haematomaSignal | 204 | 25495.0 | 17489.3 | 682,680 |
| penile swellingSignal | 479 | 2487.6 | 2224.8 | 723,585 |
| penile painSignal | 311 | 440.4 | 392.8 | 122,045 |
| contusionSignal | 671 | 27.2 | 25.3 | 16,842 |
| swellingSignal | 576 | 24.0 | 22.2 | 12,633 |
| injection site swellingSignal | 213 | 10.8 | 9.5 | 1,884 |
| inappropriate schedule of product administrationSignal | 214 | 4.6 | 4.0 | 604 |
| injection site painSignal | 322 | 4.1 | 3.7 | 752 |
| drug ineffectiveSignal | 1,359 | 4.0 | 3.8 | 3,249 |
| painSignal | 506 | 3.2 | 2.9 | 781 |
| condition aggravatedSignal | 208 | 2.6 | 2.3 | 215 |
| peyronie^s disease | 204 | 0.0 | 0.0 | 786,481 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.